Eisai and Biogen’s experimental therapy lecanemab (BAN2401) safely leads to rapid and sustained reductions in the brain levels of beta-amyloid — the protein that forms toxic clumps in Alzheimer’s — in people in early disease stages, according to one-year, preliminary data from a Phase 2 trial’s ongoing extension phase. Notably, greater beta-amyloid drops were observed in those patients assigned to a placebo for the first part of Study 201 (NCT01767311), who switched to lecanemab in the…
You must be logged in to read/download the full post.
The post #AANAM – Lecanemab Safely, Quickly Lowers Amyloid Clumps in Trial appeared first on BioNewsFeeds.